The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 13, 2020

Filed:

Jun. 07, 2013
Applicant:

Ambrx, Inc., La Jolla, CA (US);

Inventors:

Richard S. Barnett, San Marcos, CA (US);

Feng Tian, San Diego, CA (US);

Anna-Maria A. Hays Putnam, San Diego, CA (US);

Marco Gymnopoulos, San Diego, CA (US);

Nick Knudsen, Escondido, CA (US);

Andrew Beck, San Diego, CA (US);

Ying Sun, San Diego, CA (US);

Assignee:

Ambrx, Inc., La Jolla, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 47/68 (2017.01); A61K 49/00 (2006.01); C07K 16/40 (2006.01); C07K 16/30 (2006.01); C07K 5/02 (2006.01);
U.S. Cl.
CPC ...
C07K 16/40 (2013.01); A61K 47/6817 (2017.08); A61K 47/6869 (2017.08); C07K 5/0205 (2013.01); C07K 16/3069 (2013.01);
Abstract

This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αPSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αPSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.


Find Patent Forward Citations

Loading…